<DOC>
	<DOCNO>NCT01046864</DOCNO>
	<brief_summary>The purpose study determine safe maximum tolerable dose Brivanib combine standard dose 5FU/LV FOLFIRI .</brief_summary>
	<brief_title>Combination Brivanib With 5-Fluorouracil/Leucovorin ( 5FU/LV ) 5-Fluorouracil/Leucovorin/Irinotecan ( FOLFIRI )</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Histological/cytological confirm diagnosis Gastrointestinal malignancy , except pancreatic cancer Eligible 5FU/LV FOLFIRI chemotherapy ECOG 01 Able swallow tolerate tablet Life expectancy 3 month Unwilling use acceptable method avoid pregnancy partner/self entire study period 4 week last dose Women pregnant breastfeeding Pancreatic cancer Known brain metastasis , evidence leptomeningeal disease History thromboembolic disease Hemorrhage/bleeding event Uncontrolled significant cardiovascular disease Any 3 follow risk factor : arterial thrombosis , smoking , hypercholesterolemia , hypertension , obesity ( BMS &gt; 30 ) diabetes Preexisting thyroid abnormality , maintain medication QTC ( Fridericia ) &gt; 450 msec two consecutive ECG 's Subjects concomitant second malignancy ( except adequately treat nonmelanoma skin , situ carcinoma bladder , cervix breast , early prostate cancer ) Any major surgery within 4 week study drug administration Increased level DDimer Prothrombin fragment 1 +2 Arm B C onlypositive UGT1A1 genotype TA7/TA7 History allergy brivanib drug class History severe reaction fluoropyrimidine therapy irinotecan Prior therapy brivanib</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Gastro-Intestinal Cancer , NOS</keyword>
</DOC>